ROCKVILLE, Md., July 8, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced the execution of a royalty acquisition agreement (“Agreement”) with HealthCare Royalty Partners (“HC Royalty”). Per the Agreement, HC Royalty will make a $30 million cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitram™ (treprostinil) Extended-Release Tablets by Supernus’ partner United Therapeutics Corporation. Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement. - See more at: http://www.globenewswire.com/news-release/2014/07/08/649276/10088026/en/Supernus-to-Receive-30-Million-in-Non-Dilutive-Royalty-Deal.html#sthash.vyAUiSR4.dpuf
Help employers find you! Check out all the jobs and post your resume.
